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Purpose  
The purpose of these guidelines is to assist specialists in Nuclear Medicine and Radionuclide 
Radiology in recommending, performing, interpreting and reporting 18F-fluciclovine PET/CT. 
It should be recognised that adherence to the guidance in this document will not assure an 
accurate diagnosis or a successful outcome. These guidelines will assist individual 
departments in the formulation of their own local protocols. The guidelines apply to studies 
on adults. All that should be expected is that the practitioner will follow a reasonable course 
of action based on current knowledge, available resources and the needs of the patient in 
order to deliver effective and safe medical care.  
Background 
18F-Fluciclovine PET/CT is a non-invasive imaging technique which relies on the evaluation of 
amino acid metabolism in the setting of upregulated amino acid transport systems in 
prostate cancer. 18F-Fluciclovine is a synthetic amino acid which is transported by sodium-
dependent channels [specifically system ASC (ASCT2) with a contribution from sodium-
independent system L (LAT1)] [1].  
 
Goals 
This document aims to provide guidance to nuclear medicine physicians and radiologists on 
the indications for and the methods of performing and reporting 18F-fluciclovine PET/CT 
imaging in the setting of biochemical recurrence of prostate cancer, and to standardise 
quality control and assurance procedures. The guidelines are based on the best available 
evidence or, where this is lacking, on the clinical experience of the authors in consensus. 
They are intended to help departments produce studies of the highest quality and clinical 
utility. Areas for future research are also discussed. 
Definitions 
PET/CT scanner:  
An imaging instrument which allows molecular information (PET) and anatomical detail (CT) 
to be acquired sequentially as part of a single study. The two data sets can be fused 
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accurately provided there is no significant patient movement during the imaging 
acquisitions. 
Biochemical recurrence: 
A rise in serum prostate-specific antigen (PSA) in a patient post radical treatment with 
curative intent, either surgery (prostatectomy) or radiotherapy.  Also called biochemical 
relapse and PSA failure, the precise threshold of PSA rise required to determine disease 
relapse is dependent upon the initial curative treatment. 
Restaging: 
A process used to determine the amount or spread of cancer in the body in the event of 
recurrence or progression after treatment with the intention of informing the choice of 
treatment.  
 
Castrate-resistant metastatic prostate cancer (CRPC): 
Metastatic prostate cancer that has progressed following either medical or surgical 
castration. 
 
 
Indications 
18F-Fluciclovine PET/CT imaging is indicated in patients with suspicion of recurrent prostate 
cancer based on elevation of the PSA level following prior treatment with curative intent, 
and is performed with the intention of guiding or optimising salvage treatment. 
The criteria outlined in this article are based on the currently available evidence, including 
data from prospective clinical trials as well as the authors’ experience of using this tracer.  
Localisation of tumour in recurrent prostate cancer 
Published data exist on the use of 18F-fluciclovine for localisation of prostate cancer in the 
setting of biochemical recurrence [2–9]. The aim of assessment or restaging in this setting is 
to potentially guide salvage therapy. Clinically acceptable diagnostic performance was 
demonstrated in the international multicentre setting, where subject level detection rate at 
a low PSA (≤0.79 ng/ml) was 41%, with a positive predictive value of 92% for detection of 
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extra-prostatic disease [10]. Two major multicentre clinical trials have recently evaluated 
the impact of 18F-fluciclovine on the management of patients with biochemical recurrence. 
In the United States-based LOCATE trial [2], 18F-fluciclovine PET/CT led to a major change in 
management in 59% (126/213) of patients with negative or equivocal conventional imaging 
(CT/bone scan/MRI). These results are concordant with those of a similar UK study 
(FALCON), which demonstrated that 61% (52/85) of patients had a major change in 
management after an 18F-fluciclovine PET/CT scan, meeting a pre-specified condition 
defining overwhelming efficacy [11]. 
Greater diagnostic accuracy in comparison with 11C-choline PET/CT has been reported by 
Nanni et al. in 89 patients who underwent investigation with both tracers [6].  18F-
Fluciclovine PET/CT allowed more accurate restaging in patients with biochemical 
recurrence; furthermore, its sensitivity was 37% compared with 32% for 11C-choline and its 
specificity was 67% compared with 40% for 11C-choline. Greater detection of disease sites 
was particularly evident at low PSA levels (21% and 14% for 18F-fluciclovine and 11C-choline 
respectively at a PSA level of <1 ng/ml, and 45% and 29% respectively when PSA was 
between 1 and <2 ng/ml). 
 
Emerging applications 
The licenced indication for 18F-fluciclovine is limited to detecting recurrence of prostate 
cancer in adult men with biochemical recurrence of prostate cancer. Nonetheless, there are 
specific areas where conventional imaging may benefit from supplementation with PET/CT 
in prostate cancer. In the primary setting, typically in patients with high-risk disease, 
equivocal conventional findings (for example a borderline abnormal lymph node on CT or 
MRI or equivocal uptake on a bone scan) could potentially be resolved with 18F-fluciclovine. 
This is already recommended by the joint RCR-RCP guidelines for 18F-choline PET/CT and 
68Ga-PSMA PET/CT [12]. 
 
In the evaluation of the primary tumour, 18F-fluciclovine PET/CT may potentially aid the 
localisation of intra-prostatic tumour and guide targeted biopsy in cases in which MRI is 
contraindicated or severely limited (e.g. by non-resolvable artefact), with ongoing studies 
evaluating this potential indication. 
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In advanced metastatic disease, response evaluation currently relies on CT and bone scans, 
which may fail to detect progression at early intervals. Research on 18F-fluciclovine PET/CT 
in this setting may allow earlier treatment modification in CRPC. 
 
Contraindications 
Hypersensitivity, to the active substance or excipients, when used in men being investigated 
for biochemical recurrence of prostate cancer. 
 
Regulatory requirements 
 
Administration of Radioactive Substances Advisory Committee (ARSAC) licences for 
fluciclovine will normally be held by radionuclide radiology/nuclear medicine specialists. The 
prospective licence holder needs to provide proof, when applying for an ARSAC licence, that 
they have undergone appropriate theoretical and supervised practical training. Training 
materials that are suitable for submission as evidence for a practitioner license are available 
direct from Blue Earth Diagnostics Ltd .  Under the new IRMER guidelines, the site licence 
will have to show that 18F PET tracers can be used at the site [13]. 
 
18F-Fluciclovine (AxuminTM) was approved by the US Food and Drug Administration in May 
2016 and by the European Medicines Agency in May 2017 [14, 15] for for PET imaging in 
biochemical recurrence of prostate cancer. National Comprehensive Cancer Network 
guidelines published in 2018 state that fluciclovine PET/CT can be considered for recurrence 
or disease progression after definitive therapy or for disease progression during systemic 
therapy (National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in 
Oncology: Prostate Cancer Version 2.2018. June 3, 2018. Available online: 
https://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf). The 2019 European 
Association of Urology (EAU) guidelines on prostate cancer management also advocate the 
use of fluciclovine PET/CT in patients with PSA recurrence who are fit for curative salvage 
treatment (https://uroweb.org/guideline/prostate-cancer/). 
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Qualifications and responsibilities of personnel 
See European Association of Nuclear Medicine procedure guidelines for tumour PET 
imaging, version 2.0 or the Society of Nuclear Medicine and Molecular Imaging Procedure 
Standard for General Imaging [16, 17].  
 
Procedure/specification of the examination 
 
Necessary data for requesting examination 
In order for correct justification/vetting to be performed by a medical practitioner, as well 
as to improve the quality of the report of the study, key elements of the patient’s history 
should be declared on the imaging request. These include: 
• Specific question being asked (e.g. Where is the location of tumour recurrence?) 
• Diagnosis  
• Risk group (based on PSA, T stage and Gleason score) 
• Treatment history (e.g. radiotherapy or prostatectomy) 
• Current PSA values 
• Serial PSA values and PSA kinetics (velocity and doubling time) 
• Relevant findings from other investigations (e.g. MRI) 
• Current medications and allergies 
• Symptoms (e.g. bone pain) 
• Relevant co-morbidities (e.g. co-existing malignancy) 
 
Patient preparation 
 
Patients should avoid strenuous activity for 24 h prior to 18F-fluciclovine injection. Fasting is 
required for at least 4 h prior to the study with only small sips of water and any regular 
medications permissible. . To reduce the potential impact of early urinary excretion (in a 
minority of patients) into the bladder, patients should be encouraged to void approximately 
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30-60 minutes before scanning. Prior to injection, a focussed history should be taken, 
including confirmation of the reason for the study, treatment history, list of medications, 
allergies and any co-morbidities, including any clinical changes since last seeing the referring 
clinician, such as infection or trauma. Confirmation of fasting status and lack of strenuous 
activity for 24 h should be documented at this stage. 
 
Radiopharmaceutical dose 
The suggested target injected dose of 18F-fluciclovine is 370 MBq. A dose >20% below this 
target may result in suboptimal image quality. The recommended maximum volume of 
injection of undiluted 18F fluciclovine is 5 mL. The dose may be diluted with 0.9% sodium 
chloride for injection by a factor of 8. It should be noted that other factors such as patient 
size, scanning mode (2D or 3D) and proportion of bed position overlap will impact on the 
administered activity. 
 
Radiation exposure to the patient 
An administered activity of 370 MBq will result in an effective dose of 8.2 mSv. A maximum 
effective dose of 7 mSv would be expected due to the CT scan, depending on the scanner. 
Imaging procedure 
The study should be performed by two technologists or other qualified personnel. The 
administration should be carried out with the patient on the scanning couch. 
Injection in the right arm is preferred as stasis in the axillary vein on the left may be 
misinterpreted as a metastatic lymph node (Virchow’s node). 
 
After the injection has been completed, the patient should be asked to raise his arms above 
the head in preparation for the scan acquisition (to avoid beam-hardening artefacts). If the 
patients cannot tolerate this position for the duration of the study, a different patient 
positioning may be chosen. 
 
CT settings 
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The CT performed as part of the PET/CT protocol provides attenuation correction 
information and diagnostic information that is relevant to overall patient care. 
 
A number of CT protocols exist for PET/CT scanning. However, in general a high-quality CT 
acquisition for anatomical correlation and attenuation correction is recommended with 18F-
fluciclovine. In a patient with a hip prosthesis, it is advisable to modify the protocol to 
reduce the artefact [18]. 
 
A CT scout view is acquired for selection of the PET/CT axial field of view. A low-dose CT 
scan will be acquired for attenuation correction and anatomical correlation. It is 
recommended that respiration is not suspended during CT imaging, and the patient should 
be coached in shallow/quiet breathing. Gating of the PET and/or CT may benefit the 
breathing pattern. The use of intravenous or oral contrast is not required, however if 
intravenous contrast is standard of practice at a site it is recommended that this take place 
after the fluciclovine PET/CT scan. 
 
PET settings 
PET scanning should begin 3–5 min after completion of the injection administration (target 4 
min). Image acquisition should start from the proximal thigh and proceed to the base of the 
skull. The first bed position should be centered on the prostate bed (indicated by the pubic 
symphysis) and  include the femoral heads and inguinal nodes. 
 
Typical total scan time is between 20 and 30 min. The duration of acquisition over the pelvis 
(i.e. pubic symphysis to iliac crest) should be increased in order to improve the sensitivity of 
detection of disease in common sites of lymph node metastasis (e.g. GE Healthcare PET/CT 
using default bed overlap: acquire for 5 min for the first two bed positions over the pelvis 
and for 3 min per bed position for the remaining bed positions). 
The local radioactivity concentration can be measured on attenuation-corrected images 
which have been normalised for injected activity and body weight, lean body mass or body 
surface area. This can be recorded as the standardised uptake value (SUV). Multiple factors, 
including accuracy of calibration of the PET device, will influence the accuracy of the SUV. 
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After completion of the scan, the patient should be removed from the scanner and 
encouraged to void before leaving the PET facility. The patient should be encouraged to 
drink plenty of fluids and void frequently throughout the day.  
 
Local procedures for the management of patients undergoing 18F PET procedures should be 
followed (e.g. restricted contact with infants and pregnant women for 4 h post injection, 
provision of patient post-care and radiation information sheets).  
A sample standard operating protocol is presented in Appendix 1. 
 
Image reconstruction 
Reconstruction algorithms should be based on the manufacturer’s recommendations. 
Reconstruction modifications can best be achieved using the manufacturer’s guidelines in 
conjunction with the institution’s physician and physicist recommendations. Resolution 
recovery may help with the detection of small lesions, however the size criteria for image 
interpretation may change. For example, a 1 cm lesion without resolution recovery may be 
equivalent to a sub-centimetre lesion with resolution recovery. 
 
The reconstructed PET data should be corrected for decay, dead time, scatter, randoms and 
attenuation using standard algorithms provided by the scanner manufacturer. Attenuation 
correction should be performed using the low-dose CT. Iterative reconstruction should be 
used, e.g. OSEM or similar. Time of flight (ToF) reconstruction should be used when 
available. 
 
Documentation and reporting 
 
The use of standardised interpretation methodology for the assessment of 18F-fluciclovine 
PET/CT images has also been shown to enable naïve readers to achieve acceptable 
diagnostic performance and reproducibility when staging recurrent prostate cancer [19]. 
The PET/CT image review format will depend on the local workstation and software 
packages available. However, key data sets will include CT alone, 18F-fluciclovine PET 
(attenuation corrected and non-attenuation corrected) and fused PET/CT, and these should 
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be reviewed in axial, coronal and sagittal planes as well as the maximal intensity projection 
(MIP) view of the PET images. 
As described above, 18F-fluciclovine has particular benefit over 18F-choline in detecting 
disease recurrence at lower PSA levels. However, no threshold is recommended beyond 
which 18F-fluciclovine should be performed. Positive 18F-fluciclovine uptake is more likely at 
PSA >1 ng/ml with rapidly rising PSA kinetics before the PSA level of 1 ng/ml is reached. 
Evaluation of abnormal uptake of 18F-fluciclovine will require a detailed knowledge of 
physiological tracer uptake, false positives and the pathways of disease dissemination in 
prostate cancer [20]. Typical physiological sites of uptake are presented in Table 1.  
If a site of uptake is deemed pathological, the SUV measurement can be obtained and 
compared with non-target tissue background activity (Figures 1, 2). Focal lesions suspicious 
for disease will usually have uptake greater than bone marrow (L3 vertebral body is 
preferred). Small lesions (<1 cm) may still be considered metastatic if the avidity is similar to 
marrow uptake but greater than blood pool uptake. This approach holds true for disease in 
the prostate, seminal vesicles, prostate bed and lymph nodes [21]. Bone metastases are 
usually identified by focal uptake on the MIP image, with uptake typically higher in lytic than 
in sclerotic or mixed sclerotic lesions. Densely sclerotic lesions may be non-avid. 
Pitfalls in interpretation 
False positive sites of 18F-fluciclovine uptake include infection, inflammation in the prostate 
(including post radiation) and benign prostatic hypertrophy [20].  Lymph nodes may be 18F-
fluciclovine avid in the presence of infection, inflammation and other (non-prostate) 
malignancies including colon cancer, lymphoma and breast cancer. Benign bone lesions 
which may be 18F-fluciclovine avid include osteoid osteoma and degenerative changes. 
Malignant bone lesions from non-prostate malignancies may also be tracer avid, including 
multiple myeloma. Reactive lymph nodes may display tracer uptake and consideration 
should be given to potential underlying causes for this, e.g. vascular grafts. Variable uptake 
is recognised in musculoskeletal and cutaneous inflammation [20]. 
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False negative studies may occur at very low PSA levels and in the presence of densely 
sclerotic bone lesions. In a minority of patients, early bladder activity may impede disease 
detection in the prostate bed. These pitfalls are presented in Table 2. 
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Table 1: Degree of uptake at physiological sites. 
Mild Moderate Intense Heterogeneous 
Salivary glands and 
lymphoid tissue of 
Waldeyer’s ring 
Pituitary gland Liver Bone marrow 
Thyroid gland  Pancreas Cardiac and 
skeletal muscle 
Breast parenchyma    
Oesophagus and stomach   
Renal parenchyma   
Periurethral activity   
Urinary bladder wall    
Adrenal glands (can be 
intense) 
   
Small and large bowel   
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Table 2: Pitfalls in image interpretation. 
False positive causes False negative causes 
Prostate/ prostate bed 
BPH 
Post-treatment (radiotherapy)/ 
inflammation 
Infection 
 
Small-volume disease 
Early bladder activity obscuring disease 
Low-grade/indolent tumour 
 
Lymph node 
Reactive nodes, e.g. adjacent to vascular 
graft 
Other malignancy 
 
Small-volume/ micrometastatic 
involvement 
Low-grade/indolent tumour 
 
Bone 
Degenerative change 
Osteoid osteoma 
Other malignancy 
 
Densely sclerotic metastases 
Small-volume/ micrometastatic 
involvement 
Low-grade/indolent tumour 
 
Other 
Musculoskeletal and cutaneous 
inflammation 
Other malignancy 
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Figure 1: 62 year old, Previous radical prostatectomy for pT2B N0 M0, Gleason 8 disease 
Biochemical recurrence – PSA 0.6 µg/L, PSAdt  8.8 months, Intended management, Salvage 
radiotherapy to the prostatectomy bed. 
Axumin scan confirmed a 18F-fluciclovine avid focus within the prostatectomy bed at the 
vesicourethral anastomosis.  This was aided by the presence of only minimal radioactivity in the 
urinary bladder. Patient received RT limited to the prostatectomy bed. 
 
 
  
 
 
 
 
Figure 2: 71 year old man, previous radical prostatectomy for T3A N0 M0, Gleason 9 disease,  
Biochemical recurrence – PSA 0.73 µg/L. Intended management Androgen deprivation therapy. 
With positive delineation of these F18-fluciclovine avid retroperitoneal nodes, the management plan 
was revised to include targeted salvage treatment of this area.  
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Appendix 1. 
Sample SOP for 18F-fluciclovine PET/CT. 
